GlassScriptPhysician profile
Renu M Mehta
NPI 1306893375
$9,974.01
in general payments reported to CMS, 2019-2025
37 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $908 · 2021: $1,314 · 2022: $2,435 · 2023: $1,762 · 2024: $1,364 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,808 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,807.80 |
| Education | $140.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,622.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $924.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $822.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $793.32 | 2019-2025 | |
| Amgen INC. | $752.70 | 2019-2025 | Repatha, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals LP | $666.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $619.97 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.12 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $488.49 | 2022-2025 | |
| Lilly USA, LLC | $470.60 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sirtex Medical INC | $243.00 | 2022-2023 | Sir-Spheres Microspheres |
| Genzyme Corporation | $224.53 | 2022-2023 | |
| Astellas Pharma US INC | $196.04 | 2023-2024 | Veozah |
| Gt Medical Technologies, INC | $171.96 | 2025 | Gammatile |
| Atricure, INC. | $156.25 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $155.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $140.06 | 2022-2023 | |
| Silk Road Medical, INC. | $129.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $127.92 | 2021-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Biohaven Pharmaceuticals, INC. | $107.64 | 2020-2021 | |
| Dynavax Technologies Corporation | $101.93 | 2024-2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $94.60 | 2020-2025 | Nexletol |
| Hologic Sales and Service, LLC | $73.13 | 2025 | Acessa Provu System |
| Biohaven Pharmaceutical Holding Company LTD. | $56.16 | 2022 | |
| Currax Pharmaceuticals LLC | $54.62 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $41.14 | 2020-2025 | Zoryve |
| Sanofi Pasteur INC. | $39.40 | 2019-2021 | |
| Ethicon INC. | $31.24 | 2024 | Monarch Platform |
| Phathom Pharmaceuticals, INC. | $28.88 | 2024 | Voquezna |
| Allergan, INC. | $26.10 | 2019-2020 | |
| Dexcom, INC. | $22.73 | 2023 | Dexcom G6 Transmitter |
| Dermira, INC. | $17.05 | 2020 | |
| Medtronic, INC. | $16.60 | 2025 | Symplicity G3 |
| Grifols USA, LLC | $16.58 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.29 | 2025 | Spinosad, Natroba |
| Axsome Therapeutics, INC. | $14.95 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renu Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.